Peter Eickholz

Prof. Dr. Peter Eickholz

Goethe University Frankfurt am Main, Germany; Center of Dentistry and Oral Medicine
orcid

Research Focus & Metrics

Academic Career Length

33Years (1994-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
10 January 2008 in Journal of Clinical Periodontology
Verified
Journal Article
Closed access
PDF file
Peter EickholzPeter Eickholz
Peter Eickholz
JKJens Kaltschmitt
Jens Kaltschmitt
JBJanet Berbig
Janet Berbig
PRPeter Reitmeir
Peter Reitmeir
BPBernadette Pretzl
Bernadette Pretzl

18 June 2019 in Journal of Clinical Periodontology
Verified
Journal Article
Open access
PDF file
Mariano SanzMariano Sanz
Mariano Sanz
CDChrister Dahlin
Christer Dahlin
DADanae Apatzidou
Danae Apatzidou
ZAZvi Artzi
Zvi Artzi
DBDarko Bozic
Darko Bozic
HSHenning Schliephake
Henning Schliephake
Background and Aims: To review the regenerative technologies used in bone regeneration: bone grafts, barrier membranes, bioactive factors and cell therapies.Material and Methods: Four background review publications served to elaborate this consensus report.Results and Conclusions: Biomaterials used as bone grafts must meet specific requirements: biocompatibility, porosity, osteoconductivity, osteoinductivity, surface properties, biodegradability, mechanical properties, angiogenicity, handling and manufacturing processes. Currently used biomaterials have demonstrated advantages and limitations based on the fulfilment of these requirements. Similarly, membranes for guided bone regeneration (GBR) must fulfil specific properties and potential biological mechanisms to improve their clinical applicability. Pre‐clinical and clinical studies have evaluated the added effect of bone morphogenetic proteins (mainly BMP‐2) and autologous platelet concentrates (APCs) when used as bioactive agents to enhance bone regeneration. Three main approaches using cell therapies to enhance bone regeneration have been evaluated: (a) “minimally manipulated” whole tissue fractions; (b) ex vivo expanded “uncommitted” stem/progenitor cells; and (c) ex vivo expanded “committed” bone‐/periosteum‐derived cells. Based on the evidence from clinical trials, transplantation of cells, most commonly whole bone marrow aspirates (BMA) or bone marrow aspirate concentrations (BMAC), in combination with biomaterial scaffolds has demonstrated an additional effect in sinus augmentation and horizontal ridge augmentation, and comparable bone regeneration to autogenous bone in alveolar cleft repair.

10 January 2008 in Journal of Clinical Periodontology
Verified
Journal Article
Closed access
PDF file
BPBernadette Pretzl
Bernadette Pretzl
JKJens Kaltschmitt
Jens Kaltschmitt
TKTi‐Sun Kim
Ti‐Sun Kim
PRPeter Reitmeir
Peter Reitmeir
Peter EickholzPeter Eickholz
Peter Eickholz

1 February 2000 in European Journal of Oral Sciences
Verified
Journal Article
Closed access
PDF file
Peter EickholzPeter Eickholz
Peter Eickholz
EHE. Hausmann
E. Hausmann

8 January 2020 in Journal of Clinical Periodontology
Verified
Journal Article
Open access
PDF file
HDHenrik Dommisch
Henrik Dommisch
CWClemens Walter
Clemens Walter
BDBettina Dannewitz
Bettina Dannewitz
Peter EickholzPeter Eickholz
Peter Eickholz
Objective: To evaluate the benefit of resective surgical periodontal therapy (root amputation or resection, root separation, tunnelling) in periodontitis patients exhibiting class II and III furcation involvement (FI) compared with non‐surgical treatment (SRP) or open flap debridement (OFD).Material: Outcomes were tooth survival (primary), vertical probing attachment gain, and reduction in probing pocket depth (secondary) evidenced by randomized clinical trials, prospective and retrospective cohort studies and case series with ≥ 12 months of follow‐up. Search was performed on 3 electronic databases from January 1998 to December 2018.Results: From a total of 683 articles, 66 studies were identified for full‐text analysis and 7 studies finally included. Six hundred sixty‐seven patients contributed 2,021 teeth with class II or III FI. Data were very heterogeneous regarding follow‐up and distribution of FI. A total of 1,515 teeth survived 4 to 30.8 years after therapy. Survival ranged from 38%–94.4% (root amputation or resection, root separation), 62%–67% (tunnelling), 63%–85% (OFD) and 68%–80% (SRP). Overall, treatment provided better results for class II FI than class III.Conclusion: Within their limits, the data indicate that in class II and III FI, SRP and OFD may result in similar survival rates as root amputation/resection, root separation or tunnelling.

1 March 2004 in Journal of Periodontology
Verified
Journal Article
Closed access
Peter EickholzPeter Eickholz
Peter Eickholz
THTorten Hörr
Torten Hörr
FKFilip Klein
Filip Klein
SHStefan Hassfeld
Stefan Hassfeld
TKTi‐Sun Kim
Ti‐Sun Kim
Background: The aim of the present study was to evaluate defect width and two different definitions of defect depth as prognostic factors of periodontal healing in infrabony defects treated by regenerative therapy 6 and 24 months after surgery.Methods: In 32 patients with moderate to advanced periodontitis, 50 infrabony defects were treated by the guided tissue regeneration (GTR) technique using non‐resorbable or bioabsorbable barriers. Clinical parameters were assessed, and 50 triplets of standardized radiographs were taken before surgery and 6 and 24 months after surgery. Using a computer‐assisted analysis, the distances cemento‐enamel junction (CEJ) to alveolar crest (AC), CEJ to bony defect (BD), horizontal projection of the most coronal extension of the bony wall to the root surface to BD, width, and angle of the bony defects were measured. Depth of the bony defect was 1) calculated as CEJ‐BD minus CEJ‐AC (INFRA1) and 2) measured as horizontal projection of the most coronal extension of the bony wall to the root surface to BD (INFRA2).Results: Whereas statistically significant vertical clinical attachment level gains (CAL‐V: 3.36 ± 1.59 mm/ 3.41 ± 1.72 mm; P <0.001) could be found both 6 and 24 months after surgery, bony fill (0.70 ± 2.52 mm; P = 0.056/1.21 ± 2.55 mm; P <0.005) was significant 24 months post‐surgically only. In a multilevel regression analysis, CAL‐V gain was predicted by bioabsorbable membrane (P = 0.005), baseline probing depths (PD) (P <0.001), and actual smoking (P <0.05). Bony fill could be predicted by baseline depth of the infrabony component as determined by INFRA2 (P <0.05), angulation of bony defect (P <0.005), and gingival index at baseline (P <0.001). In narrow (<37°) and deep (≥4 mm) infrabony defects, bony fill was more pronounced than in wide and shallow defects (P <0.001).Conclusions: Improvement achieved by GTR in infrabony defects can be maintained up to 24 months after surgery. Narrow and deep infrabony defects respond radiographically and are to some extent clinically more favorable to GTR therapy than are wide and shallow defects. The infrabony component of bony defects, as determined by the distance from the most coronal extension of the lateral bony wall to BD (INFRA2), is a better predictor of bony fill than that determined by AC‐BD (INFRA1). J Periodontol 2004;75:399‐407.